DiagnoCure to present at the JMP Securities Healthcare Focus Conference on Octob...( Ticker Symbol: CUR QUEBEC CITY...),Health

Ticker Symbol: CUR

QUEBEC CITY, Oct. 1 /PRNewswire-FirstCall/ - DiagnoCure Inc. (TSX: CUR), a life sciences company commercializing high-value cancer diagnostic tests and delivering laboratory services, announced today that Mr. John Schafer, President and CEO of the Company, will be presenting a company overview at the Third Annual JMP Securities Healthcare Focus Conference on Monday, October 6, 2008, at 1:30 PM (ET). This conference is taking place in New York (New York) on October 6 and 7, 2008.

The event will be webcast live through DiagnoCure's website at http://www.diagnocure.com, through a link on the Investors page - Presentations and Conferences. An archived presentation will be available on the Web site for 90 days.

More information on the Third Annual JMP Securities Healthcare Focus Conference can be found at http://www.jmpsecurities.com.

About DiagnoCure

DiagnoCure (TSX: CUR) is a life sciences company commercializing high-value cancer diagnostic tests and delivering laboratory services that increase clinician and patient confidence in making critical treatment decisions. DiagnoCure Oncology Laboratories, a subsidiary of DiagnoCure Inc., recently launched the Previstage(TM) GCC Colorectal Cancer Staging Test, the first GCC-based molecular test for the management of colorectal cancer. The Company also has a strategic alliance with Gen-Probe (NASDAQ: GPRO) for the development and commercialization of a second-generation prostate cancer test using PCA3, DiagnoCure's proprietary molecular marker. This test is also available through laboratories in the U.S. using PCA3 analyte specific reagents (ASR) from Gen-Probe, in Europe as the CE-marked PROGENSA(TM) PCA3 in vitro assay, and in Canada. In addition to its own research, the Company intends to acquire or in-license additional promising cancer biomarkers from
'/>"/>